Immunotherapy has become a rapid, remarkable success. Now, the results of a clinical trial by Rita Nanda, MD, becomes the first published report to show its effectiveness against triple-negative breast cancer. [Read more]

What if our immune system could be mobilized to attack a tumor in the same way it fights the common cold or fends off an infection? Cancer experts at UChicago are leading the way in unleashing the body's ability to fight back. [Read more]

Early results of a clinical trial by Dr. Rita Nanda show that nearly 20% of patients with triple-negative breast cancer--which currently has no targeted treatments--respond to a drug called pembrolizumab. [Read more]

The University of Chicago Medicine Comprehensive Cancer Center conducts more clinical trials than any other facility in Illinois. In honor of National Cancer Research Month, we continue our focus on research and outcomes. [Read more]

Triple negative breast cancers represent a particularly aggressive form of breast cancer. Although they represent about 10-20% of newly diagnosed invasive breast cancers, patients with TNBC often suffer worse outcomes compared to those with other subsets. We're researching ways to improve outcomes for these patients. [Read more]

Geoffrey L. Greene, PhD, the Virginia and D.K. Ludwig Professor for Cancer Research at the University of Chicago, has been named chair of the Ben May Department for Cancer Research, effective Sept. 1, 2013. [Read more]

A high percentage of African-American women with breast cancer who were evaluated at a university cancer-risk clinic were found to carry inherited genetic mutations that increase their risk for breast cancer. [Read more]